|1.||Pashko, Laura L: 2 articles (05/2003 - 02/2002)|
|2.||Schwartz, Arthur G: 2 articles (05/2003 - 02/2002)|
|3.||Lubet, Ronald A: 1 article (02/2007)|
|4.||Kozub, Nicole M: 1 article (02/2007)|
|5.||Johnson, William D: 1 article (02/2007)|
|6.||Bosland, Maarten C: 1 article (02/2007)|
|7.||Steele, Vernon E: 1 article (02/2007)|
|8.||Rao, K V N: 1 article (02/2007)|
|9.||McCormick, David L: 1 article (02/2007)|
|10.||Morgan, Elizabeth E: 1 article (02/2004)|
02/01/2004 - "In the present studies, we tested the ability of fluasterone to limit disease in the DBA mouse model of collagen-induced arthritis (CIA). "
02/01/2002 - "This report discusses how fluasterone ameliorates the development of joint inflammation in an adjuvant-arthritis model in Lewis rats."
|2.||Brain Injuries (Brain Injury)
|4.||Prostatic Neoplasms (Prostate Cancer)
02/01/2007 - "On this basis, fluasterone merits consideration for evaluation in clinical trials for prostate cancer prevention. "
11/01/2003 - "Difluoromethylornithine (DFMO), DHEA analogue 8354 (fluasterone), and oltipraz did not show strong inhibitory effects on the growth or survival of normal prostate epithelial cells, 267B1 or 267B1/Ki-ras cells, suggesting that these agents may not be effective as prostate cancer preventive or therapeutic agents."
02/01/2002 - "We have developed a synthetic congener of DHEA called fluasterone that, in animal tests, lacks the androgenicity, estrogenicity, and peroxisome-proliferating effects of DHEA but retains the cancer-preventive, antidiabetic, and anti-inflammatory efficacy. "
11/01/2001 - "In addition, fluasterone, fenretinide and soy each delayed tumor development but had little effect on IGF-1 or leptin levels. "
|4.||Insulin-Like Growth Factor I (IGF-1)